Biosimilars—Advances in Research and Development

This course was last updated on
June 15, 2017
CME credit has expired.
Enter your information to begin.

Steven R. Feldman, MD, PhD, summarizes the latest information on the advances in biosimilar research and development, while providing clinical implications of recent clinical data and ongoing trials involving biosimilars in relation to the data for their reference biological product. The goal of this program is to raise awareness about biosimilars, and discuss recent data, which may provide more trust in the use of biosimilars and ultimately prove beneficial to patients.

Content Areas

  • Glycosylated biopharmaceuticals reviewed
  • Totality-of-the-evidence approach
  • GP2015, a proposed etanercept biosimilar
  • CT-P13, an infliximab biosimilar
  • GP2017, an adalimumab biosimilar
  • Unanswered questions about biosimilars

Target Audience

This activity was developed for rheumatologists, dermatologists, gastroenterologists, and other health care professionals who have an interest in biosimilars.


Steven R. Feldman, MD, PhD
Steven R. Feldman, MD, PhD
Professor of Dermatology, Pathology and Public Health Sciences
Department of Dermatology
Wake Forest University School of Medicine
Winston-Salem, North Carolina
CME Credit
Available Credit: 1.50 AMA PRA Category 1 Credits™.
Opens: June 15, 2017
Expires: June 14, 2018
Target Audience: Rheumatologists
Other Health Care Providers
Supported by an independent medical education grant from Sandoz, Inc., a Novartis Division.